Cantor Fitzgerald Estimates CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($5.08) per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the firm posted ($1.41) earnings per share.

Several other analysts also recently weighed in on CRSP. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Stock Up 6.5 %

Shares of NASDAQ CRSP opened at $44.20 on Wednesday. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The business has a fifty day simple moving average of $44.43 and a two-hundred day simple moving average of $47.88. The firm has a market cap of $3.77 billion, a PE ratio of -15.62 and a beta of 1.68.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of CRSP. American Century Companies Inc. increased its stake in shares of CRISPR Therapeutics by 4.0% in the second quarter. American Century Companies Inc. now owns 18,411 shares of the company’s stock worth $994,000 after acquiring an additional 703 shares during the period. Dimensional Fund Advisors LP grew its position in CRISPR Therapeutics by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after purchasing an additional 19,094 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of CRISPR Therapeutics by 4.3% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 10,787 shares of the company’s stock valued at $583,000 after buying an additional 447 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of CRISPR Therapeutics by 13.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,167 shares of the company’s stock valued at $225,000 after buying an additional 486 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in CRISPR Therapeutics in the second quarter valued at approximately $1,449,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.